Fast Market Research

Just Released: "Immatics Biotechnologies GmbH - Product Pipeline Review - 2012"

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research


Boston, MA -- (SBWIRE) -- 02/27/2013 -- Global Market Direct's pharmaceuticals report, "immatics biotechnologies GmbH - Product Pipeline Review - 2012" provides data on the immatics biotechnologies GmbH's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, immatics biotechnologies GmbH's corporate website, SEC filings, investor presentations and featured press releases, both from immatics biotechnologies GmbH and industry-specific third party sources, put together by Global Markets Direct's team.


- immatics biotechnologies GmbH - Brief immatics biotechnologies GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of immatics biotechnologies GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of immatics biotechnologies GmbH with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the immatics biotechnologies GmbH's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate immatics biotechnologies GmbH's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of immatics biotechnologies GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the immatics biotechnologies GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with immatics biotechnologies GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of immatics biotechnologies GmbH and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Immatics biotechnologies GmbH - Product Pipeline Review - H2 2011
- immatics biotechnologies GmbH - Product Pipeline Review - Q1 2011
- Astrocytoma - Pipeline Review, H1 2012
- Glioma - Pipeline Review, H2 2012
- Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2012
- Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2012
- Renal Cell Carcinoma - Pipeline Review, H1 2012
- Astrocytoma - Pipeline Review, H2 2012
- Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012
- Carcinomas - Pipeline Review, H2 2012